Table 2

Characteristics of randomised controlled trials comparing latanoprost and timolol

 Trial (ref)DesignLatanoprost (%)Timolol (%)LocationLengthNoWithdrawals (%)Sex (M/F)Mean age (range, years)Types of glaucomaBaseline IOP (mean (SE))End point IOP (mean (SE))
POAGOHOthersLatanoprostTimololLatanoprostTimolol
Alm et al 1995 (27)DB-P, DB-C0.005 eve/mor0.5 bidScand6 months26715 (6)116/15167 (40–85)911235325.3 (0.5)24.6 (0.3)17.0 (0.4)17.9 (0.3)
Aquinoet al 1999 (28)DB-P0.005 eve0.5 bidPhilippines3 months60//////29.92918.819.6
Camras et al 1996 (29)DB-P0.005 eve0.5 bidUSA6 months26820 (7)114/15462 (30–90)841701425.325.3//
Drance et al 1998 (30)DB-C0.005 eve0.5 bidCanada3 weeks363 (8)24/1267360015.4 (0.4)15.3 (0.4)11.8 (0.3)12.2 (0.3)
Diestelhorstet al 1997 (31)DB-P, DB-C0.0015/0.005 bid/eve0.5 bidGermany6 weeks3020 (7)9/2162 (40–79)250528.1 (2.6)27.2 (1.4)19.8 (2.5)22.6 (0.9)
Diestelhorst et al1998 (32)DB-P0.005 eve0.5 bidGermany1 month462 (7)20/2660 (20–77)420425.2 (1.2)24.8 (0.9)20.3 (0.8)22.7 (1.1)
Mastropasqua et al1999 (33)DB-P0.005 eve0.5 bidItaly12 months362 (6)21/1546 (35–58)003624.524.0//
Mishimaet al 1996 (34)DB-P0.005 mor0.5 bidJapan3 months18421 (11)87/9157 (22–81)///23.1 (0.2)23.1 (0.2)16.8 (0.3)18.8 (0.3)
Nicolela et al 1996 (35)DB-C0.005 mor0.5 bidCanada1 week150 (0)7/863 (47–80)96026.7 (1.3)26.7 (1.3)19.9 (0.9)21.4 (0.6)
Rulo et al 1994 (36)SB-P0.006 bid0.5 bidHolland1 week201 (5)8/1263 (40–84)218028.5 (1.8)24.2 (0.9)//
Watson et al 1996 (37)DB-P0.005 eve0.5 bidUK6 months29426 (9)191/10365 (39–88)1211482526.2 (0.3)26.5 (0.3)17.1 (0.2)17.7 (0.2)
Total1256110 (9)597593410465137
  • No = number of patients; IOP = intraocular pressure (mm Hg); SE = standard error.

  • DB-P = double blind parallel, SB-P = single blind parallel, DB-C = double blind crossover, DB-P, DB-C = parallel design between latanoprost and timolol, but crossover design between different regimens of latanoprost. For example, in Alm's study,27patients receiving latanoprost were divided into two groups, one received latanoprost in the morning and placebo in the evening for 3 month and then latanoprost in the evening and placebo in the morning, another started with evening application and then switched after 3 months. In Diestelhorst's report,31 20 patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a crossover design. Ten patients received timolol 0.5% twice daily as control.

  • / = not reported.

  • POAG = primary open angle glaucoma, OH = ocular hypertension, Others = including other types of open angle glaucoma, eg, exfoliation syndrome and pigment dispersion syndrome.

  • Scand = Scandinavia.

  • mor = morning regimen, eve = evening regimen, bid = twice per day.